Gastric Cancer Clinical Trial
Official title:
Long-term Outcomes of Open Versus Laparoscopic Distal Gastrectomy for T4a Gastric Cancer: a Propensity Score-matched Cohort Study
NCT number | NCT05493358 |
Other study ID # | 71/GCN-HÐÐÐ |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2013 |
Est. completion date | June 30, 2022 |
Verified date | August 2022 |
Source | University Medical Center Ho Chi Minh City (UMC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
There are more than 75% of patients with gastric cancer who are diagnosed in advanced stage in Vietnam, most of cases in T4a. The purpose of this study was to compare short- and long- term outcomes of open and laparoscopic distal gastrectomy for gastric adenocarcinoma in surgical T4A stage.
Status | Completed |
Enrollment | 472 |
Est. completion date | June 30, 2022 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 90 Years |
Eligibility | Inclusion Criteria: - patients with histologically confirmed adenocarcinoma of the stomach, surgical staging of sT4aN0-3M0 according to the 7th edition of the American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) staging system Exclusion Criteria: - intraoperatively detected bulky lymph nodes - inadequate lymphadenectomy (D0, D1, D1+) - macroscopic residual tumor (R2) - an American Society of Anaesthesiology (ASA) score of > IV - concurrent cancer or history of previous other cancers - previous gastrectomy - neoadjuvant chemotherapy - complications such as bleeding or perforation required emergency gastrectomy. |
Country | Name | City | State |
---|---|---|---|
Vietnam | University Medical Center Ho Chi Minh City | Ho Chi Minh City |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Ho Chi Minh City (UMC) |
Vietnam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 5 year overall survival by Kaplan Mayer | The percentage of people in this study who are alive five years after surgery. | 5 year after surgery | |
Primary | 5 year disease-free survival by Kaplan Mayer | The percentage of people in this study who are alive without recurrence/metastasis five years after surgery. | 5 year after surgery | |
Secondary | 1 year overall survival by Kaplan Mayer | The percentage of people in this study who are alive one years after surgery. | 1 year after surgery | |
Secondary | 3 year overall survival by Kaplan Mayer | The percentage of people in this study who are alive one years after surgery. | 3 year after surgery | |
Secondary | 1 year disease-free survival by Kaplan Mayer | The percentage of people in this study who are alive without recurrence/metastasis one years after surgery. | 1 year after surgery | |
Secondary | 3 year disease-free survival by Kaplan Mayer | The percentage of people in this study who are alive without recurrence/metastasis one years after surgery. | 3 year after surgery | |
Secondary | operative morbidity | The overall rate of postoperative complications | 30 days after surgery | |
Secondary | operative time | The duration of a surgical procedure in minutes. | intraoperative | |
Secondary | operative blood loss | The amount of blood lost during procedure | intraoperative | |
Secondary | time to flatus | Number of days from date of surgery until date of flatus | 30 days after surgery or until mortality ] | |
Secondary | Postoperative hospital length of stay | Number of days from date of surgery until date of discharge or mortality | 30 days after surgery or until mortality | |
Secondary | The percentage of complications with Clavien-Dindo | The percentage of complication grade by Clavien-Dindo classification | 30 days after surgery | |
Secondary | The percentage of pattern of recurrence/metastasis | The percentage of pattern of recurrence/metastasis during follow up period | 5 year after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |